Navigation Links
Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
Date:2/19/2008

pment. In addition to the over 56 ErbB-targeted agents in development (35 in current clinical trials), numerous molecular markers/pathways are being recognized as contributing to the success or failure of the ErbB pathway inhibitors. A series of reports (http://www.newmedinc.com/futonc/sample.pdf) on currently approved therapeutics as well as those in development targeting the ErbB pathway, including EGFr and HEr2 inhibitors, published by Future Oncology (http://www.newmedinc.com), highlights the contribution of molecular profiling in the characterization of cancer and its treatment.

New Medicine's Oncology KnowledgeBASE (nm|OK) is a Complete Knowledge Environment in Drug Development in Cancer

Unlike standard drug databases, nm|OK residing at http://www.nmok.net, is designed to specifically provide a fully realized environment reflecting every aspect of drug development in oncology. nm|OK is an edited, inclusive analysis of all aspects of oncology drug development worldwide, including technologies, targets, companies, business affiliations, medical and clinical developments, protocols and results of thousands of clinical trials, and global markets, among others. Currently, nm|OK profiles over 2,000 anticancer agents/technologies in current development (over 4,000 drugs overall) or on the market, more than 1,200 targets implicated in malignancy, and more than 2,000 companies developing/marketing products in the oncology sector. Protocols, interim and final results are presented for thousands of trials, searchable by both novel and approved agents in monotherapy or combination therapy regiments. In addition, nm|OK describes hundreds of diagnostic, prognostic, and theragnostic methodologies and products as they relate to treatment candidate selection, evaluation of the results of clinic
'/>"/>

SOURCE New Medicine, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Preliminary PI-88 Phase 2 Prostate Cancer Results to be Presented at the American Society for Clinical Oncology (ASCO) 2008 Genitourinary Cancer Symposium
2. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
3. US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium
4. Pharsight Uses FDA Disease Model to Support Oncology Drug Development
5. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
6. University of Pennsylvania School of Medicine Study Shows Significant Differences in English- and Spanish-speakers Use of Oncology Websites
7. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
8. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
9. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
10. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
11. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... HILL, N.C. , Nov. 21, 2014 /PRNewswire/ ... healthcare system. Undoubtedly, the growing influence of patients ... spend for marketing interactions. Now, more than ever, ... retain patients for medical products is essential. ... firm, Best Practices, LLC, benchmarked companies spent about ...
(Date:11/21/2014)... , Nov. 21, 2014  Tandem Diabetes ... ), a medical device company and manufacturer of ... a partnership with Tidepool, a non-profit dedicated to ... source software platform that increases diabetes data accessibility. ... Platform, which is currently under development, to download ...
(Date:11/21/2014)... Ill. , Nov. 21, 2014  Heated dialogue ... drug prices – from cancer treatments to Gilead,s new ... pharmaceutical leaders around the world questioning what it means ... of care. And while drug pricing ... pharmaceutical industry – from both a general business and ...
Breaking Medicine Technology:New Report Details Importance of Adopting a "Patient Journey" Framework in Marketing 2Tandem Diabetes Care Announces Partnership with Tidepool to Further Expand Access to Diabetes Device Data 2Tandem Diabetes Care Announces Partnership with Tidepool to Further Expand Access to Diabetes Device Data 3"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 2"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 3"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 4"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 5
... and SOUTH SAN FRANCISCO, May 18, 2011 Bayer HealthCare ... ) today announced that data evaluating the use of Nexavar® ... the 2011 Annual Meeting of the American Society of Clinical ... and Onyx remain committed to researching the potential utility of ...
... JOSE, Calif., May 18, 2011 Oclaro, Inc. ... of optical communications and laser solutions, today outlined its ... technology direction of future products.  As a leading provider ... able to leverage its world-class manufacturing operations, technology expertise ...
Cached Medicine Technology:Nexavar Data to Be Presented at American Society of Clinical Oncology Annual Meeting 2Nexavar Data to Be Presented at American Society of Clinical Oncology Annual Meeting 3Nexavar Data to Be Presented at American Society of Clinical Oncology Annual Meeting 4Nexavar Data to Be Presented at American Society of Clinical Oncology Annual Meeting 5Nexavar Data to Be Presented at American Society of Clinical Oncology Annual Meeting 6Nexavar Data to Be Presented at American Society of Clinical Oncology Annual Meeting 7Oclaro Provides Complete Fiber Laser Diode Solutions Portfolio; Outlines Future Innovation and Technology Advancements 2Oclaro Provides Complete Fiber Laser Diode Solutions Portfolio; Outlines Future Innovation and Technology Advancements 3
(Date:11/23/2014)... Locks-Magnetic.com, a notable magnetic locks maker, has released a ... are available at low rates up to 30% off. ... new emergency doors. The emergency door adopts fireproof material ... several colors. All of the products are top-quality guaranteed. ... not as easy as many people think. As ...
(Date:11/23/2014)... (PRWEB) November 23, 2014 More than ... month in a federal litigation involving Byetta lawsuits ( ... medications, Bernstein Liebhard LLP reports. , A Case ... over a class of Type 2 diabetes medications referred ... the U.S. District Court, Southern District of California, where ...
(Date:11/23/2014)... Falls Church, VA (PRWEB) November 23, 2014 ... and TV Have in Common, **FDAnews On-Demand Webinar**, Dec. ... http://www.fdanews.com/TheFDAisWatchingOnDemand , The FDA’s focus on promotional ... ads. , Now they're looking at websites, ... , Mark the calendar for Thursday, Dec. 11, for ...
(Date:11/23/2014)... 23, 2014 Today Zane Benefits, ... small businesses, announced their new on demand webinar ... Employer-Provided Health Insurance. , According to ... financial risk facing most American families. It is ... and large, when it comes to recruiting and ...
(Date:11/22/2014)... PrettyTailor , an outstanding dress company, ... promotion. Customers can buy new dresses at its online ... its website. , As a matter of fact, PrettyTailor ... mainly provides four types of wedding outfits, including bridesmaid ... dresses. It also provides a variety of occasion dresses, ...
Breaking Medicine News(10 mins):Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 3Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 4Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 3Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 4Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 5Health News:Zane Benefits, Inc. Announces New Webinar on The End of Employer-Provided Health Insurance Now Available On-Demand! 2Health News:Customers Are Welcome to Shop at PrettyTailor.com 2
... , , LAS VEGAS, July ... that its Board of Directors has approved $50,000 in contributions to ... and $50,000 for The International Problem Gambling Center in Las Vegas. ... support of organizations dedicated to the issue of problem gambling. , ...
... , , NORFOLK, Va., July 27 ... Va., has won a contract to provide administrative services for ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20090106/PH55551LOGO ... has set up a service center in Linthicum, where 51 ...
... , , , ... Solutions Alliance today announced Kiwok Nordic AB as the winner ... Awards. Judges selected Kiwok for its BodyKom Series remote ECG ... allows heart patients to live independently while their heart is ...
... , , WILLOW ... affected by HIV/AIDS and poverty just hours before they were scheduled ... cancelled. The session, part of the organization,s Camp Heartland program, was ... commonly known as the Swine Flu. , , ...
... July 27 Quark Pharmaceuticals, Inc., a development-stage pharmaceutical ... today announced data suggesting that QPI-1007 prevents progressive retinal ... (IOP) rat model of glaucoma. The experiments performed by ... and Cell Biology, Universite de Montreal, indicate that QPI-1007 ...
... , , , ... (OTC Bulletin Board: ACCP) announced today that its ... MuGard in Norway. This follows previous commercial launches ... Pharmaceuticals, SpePharm is responsible for manufacturing, regulatory approval and commercialization in the ...
Cached Medicine News:Health News:Association of Gaming Equipment Manufacturers (AGEM) Announces $100,000 in Contributions to Organizations Working to Assist Problem Gamblers 2Health News:Association of Gaming Equipment Manufacturers (AGEM) Announces $100,000 in Contributions to Organizations Working to Assist Problem Gamblers 3Health News:ValueOptions Wins Maryland Mental Health Contract 2Health News:Itanium Solutions Alliance Selects Sweden's Kiwok as the 2009 Innovation Awards Winner for Humanitarian Impact 2Health News:Itanium Solutions Alliance Selects Sweden's Kiwok as the 2009 Innovation Awards Winner for Humanitarian Impact 3Health News:Itanium Solutions Alliance Selects Sweden's Kiwok as the 2009 Innovation Awards Winner for Humanitarian Impact 4Health News:Itanium Solutions Alliance Selects Sweden's Kiwok as the 2009 Innovation Awards Winner for Humanitarian Impact 5Health News:Itanium Solutions Alliance Selects Sweden's Kiwok as the 2009 Innovation Awards Winner for Humanitarian Impact 6Health News:H1N1 'Swine Flu' Leads to Cancellation of HIV/AIDS Summer Camp. One Heartland Announces Campaign to Fund Alternative Camp Session for 82 Children. 2Health News:Quark Pharmaceuticals Announces Data Indicating Potential Utility of QPI-1007 for Treatment of Glaucoma 2Health News:Quark Pharmaceuticals Announces Data Indicating Potential Utility of QPI-1007 for Treatment of Glaucoma 3Health News:Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Norway by SpePharm 2Health News:Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Norway by SpePharm 3Health News:Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Norway by SpePharm 4
Colloidal Gold Sol, 40 nm - 12 - 15, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
... magnification all glass (1.5x) Gonio lens will ... ease., The 4 mirror lens is the ... dynamic gonioscopy and features : , ... appreciate details previously unattainable with Gonio lenses., ...
Colloidal Gold Sol, 20 nm - 50 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
... The PalmScan P2000 Pachymeter [i.e., PalmScan ... portable,battery operated biometer, which incorporates A-mode ... used to accurately measure the corneal ... human eyes. PalmScan P2000 includes two ...
Medicine Products: